DSpace Repository

Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model

Show simple item record

dc.contributor.author Elcioglu, H. Kubra
dc.contributor.author Aslan, Ersin
dc.contributor.author Ahmad, Sarfraz
dc.contributor.author Alan, Saadet
dc.contributor.author Salva, Emine
dc.contributor.author Elcioglu, O. Haluk
dc.contributor.author Kabasakal, Levent
dc.date.accessioned 2019-09-09T11:03:05Z
dc.date.available 2019-09-09T11:03:05Z
dc.date.issued 2016
dc.identifier.citation Elcioglu, HK . Aslan, E. Ahmad, S. Alan, S . Salva, E. Elcioglu, OH . Kabasakal, L. (2016). Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model.Cilt:420. Sayı:2. 21-28 ss. tr_TR
dc.identifier.uri http://hdl.handle.net/11616/13915
dc.description.abstract Neuroinflammation plays pivotal roles in the pathogenesis of Alzheimer's disease (AD). IL-6 is pleiotropic cytokine which plays significant pathological role in inflammatory diseases and causes prolonged inflammation. Additionally, IL-6 activates microglia cells and enhances the accumulation of amyloid-beta peptides. Moreover, IL-6 signal transduction is mediated by membrane-bound and soluble IL-6 receptors. Tocilizumab which is a humanized anti-human IL-6 receptor (IL-6R) monoclonal antibody binds to both of these receptors and inhibits IL-6 signaling by this route. The objective was to investigate tocilizumab's potential effects in the treatment of AD. Male Sprague-Dawley rats were divided into three groups: sham (control), streptozotocin (STZ), and tocilizumab-STZ. We used a single dose of intracerebroventricular (ICV) tocilizumab, beginning 1 h prior to injection of STZ for 3 weeks. The rats in STZ and tocilizumab-STZ groups were given ICV-STZ (3 mg/kg). Behavioral parameters were evaluated on days 17-20 and the rats were sacrificed on day-21 to examine histopathological changes. STZ injection caused significant decrease in the mean escape latency in passive avoidance and also declined the performance improvement in Morris water maze tests. Tocilizumab-STZ group significantly improved learning and spatial memory functions by increasing RLT in the passive avoidance and by shortening escape latency in reaching the platform in the Morris water maze. Histopathological changes were examined using hematoxylin and eosin and immunohistochemical (IHC) stainings. IHC analysis revealed that while protein expressions of amyloid- (3.5 +/- A 0.2) and IL-6 (2.9 +/- A 0.4) showed intense immune-positivity in STZ group, amyloid- (1.3 +/- A 0.1) and IL-6 (1.5 +/- A 0.2) immunoreactivities were substantially decreased in tocilizumab treatment group. We conclude that tocilizumab treatment attenuated significantly STZ-induced cognitive impairment and histopathological changes. Further studies would be desirable to investigate clinically relevant protective effects of tocilizumab in AD. tr_TR
dc.language.iso eng tr_TR
dc.publisher Sprınger, van godewıjckstraat 30, 3311 gz dordrecht, netherlands tr_TR
dc.relation.isversionof 10.1007/s11010-016-2762-6 tr_TR
dc.rights info:eu-repo/semantics/openAccess tr_TR
dc.subject Autoımmune-dıseases tr_TR
dc.subject rat model tr_TR
dc.subject memory tr_TR
dc.subject ınterleukın-6 tr_TR
dc.subject dysfunctıon tr_TR
dc.subject ımpaırment tr_TR
dc.subject dementıa tr_TR
dc.subject thalıdomıde tr_TR
dc.subject ınhıbıtıon tr_TR
dc.subject expressıon tr_TR
dc.title Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model tr_TR
dc.type article tr_TR
dc.relation.journal Molecular and cellular bıochemıstry tr_TR
dc.contributor.department İnönü Üniversitesi tr_TR
dc.identifier.volume 420 tr_TR
dc.identifier.issue 2 tr_TR
dc.identifier.startpage 21 tr_TR
dc.identifier.endpage 28 tr_TR


Files in this item

This item appears in the following Collection(s)

Show simple item record